Table 1. Socio-demographic and clinical characteristics of HIV-infected women with CD4+ cell count ≥250 cells/mm3 at enrollment and who initiated PMTCT prophylactic regimens.
| Total | sd-NVP | sc-ARVp | tARVp | p-value | |
| Number | 1393 | 689 (49.5) | 532 (38.2) | 172 (12.3) | |
| Age (years)*, n (%) | |||||
| Median (IQR) | 27 (23–30) | 26 (23–30) | 27 (24–31) | 27 (23–30) | 0.02 |
| <25 | 558 (35.3) | 264 (38.4) | 172 (32.3) | 54 (31.4) | 0.10 |
| Education (years), n (%) | |||||
| Median (IQR) | 9 (7–12) | 8 (7–11) | 9 (6–12) | 9 (8–12) | 0.001 |
| 12+ | 363 (22.9) | 144 (20.9) | 125 (23.5) | 39 (20.5) | <0.001 |
| Unknown | 180 (11.4) | 42 (6.1) | 107 (20.1) | 12 (6.7) | |
| CD4+ (cell/mm3), n (%) | |||||
| Median (IQR) | 469 (361–613) | 482 (362–639) | 463.5 (363–597) | 449 (367–577) | 0.36 |
| 250–349 | 353 (22.3) | 155 (22.5) | 116 (21.8) | 33 (19.2) | 0.13 |
| 350–500 | 543 (34.3) | 217 (31.5) | 191 (35.9) | 71 (41.3) | |
| >500 | 687 (43.4) | 317 (46.0) | 225 (42.3) | 68 (39.5) | |
| WHO clinical stage, n (%) | |||||
| Stage 1 | 1117 (80.2) | 566 (82.1) | 381 (71.6) | 170 (98.8) | <0.001 |
| Stage 2 | 223(16.0) | 92 (13.4) | 131 (24.6) | 0 (0.0) | |
| Stage 3 | 52 (3.7) | 30 (4.4) | 20 (3.8) | 2 (1.2) | |
| Stage 4 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Unknown | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) | |
| Country, n (%) | <0.001 | ||||
| Cameroon | 276 (19.8) | 156 (22.6) | 120 (22.6) | 0 (0.0) | |
| Côte d’Ivoire | 290 (20.8) | 17 (2.5) | 273 (51.3) | 0 (0.0) | |
| Kenya | 237 (17.0) | 162 (23.5) | 0 (0.0) | 75 (43.6) | |
| Uganda | 119 (8.6) | 90 (13.1) | 29 (5.5) | 0 (0.0) | |
| Mozambique | 37 (2.7) | 36 (5.2) | 1 (0.2) | 0 (0.0) | |
| Rwanda | 59 (4.2) | 59 (8.6) | 0 (0.0) | 0 (0.0) | |
| South Africa | 82 (5.9) | 11 (1.6) | 71 (13.4) | 0 (0.0) | |
| Thailand | 133 (9.6) | 0 (0.0) | 36 (6.8) | 97 (53.4) | |
| Zambia | 160 (11.5) | 158 (22.9) | 2 (0.4) | 0 (0.0) | |
| Year of enrollment, n (%) | <0.001 | ||||
| 2003 | 181 (13.0) | 114 (16.5) | 55 (10.3) | 12 (7.0) | |
| 2004 | 408 (29.3) | 223 (32.4) | 81 (15.2) | 104 (60.5) | |
| 2005 | 326 (23.4) | 197 (28.6) | 74 (13.9) | 55 (32.0) | |
| 2006 | 250 (17.9) | 122 (17.7) | 127 (23.9) | 1 (0.5) | |
| 2007 | 228 (16.4) | 33 (4.8) | 195 (36.7) | 0 (0.0) |
PMTCT, prevention of mother-to-child transmission of HIV; sd-NVP, single-dose nevirapine; sc-ARVp, short-course antiretroviral prophylaxis; tARVp, triple-drug antiretroviral prophylaxis; IQR, interquartile range; CD4+, CD4+ cell count.